A traditional Chinese medicine composition with weight loss effect and its application

Abstract

This invention discloses a traditional Chinese medicine composition with weight-loss effects and its application. The formula and weight parts of the traditional Chinese medicine composition are as follows: 5-10 parts roselle, 5-10 parts lotus leaf, 2-6 parts cassia seed, 2-6 parts radish seed, 2-6 parts coix seed, 2-6 parts poria cocos, 1-2 parts blood orange, 1-3 parts codonopsis pilosula, 1-2 parts astragalus membranaceus, 1-2 parts euryale ferox, 1-3 parts dendrobium officinale, 1-3 parts ophiopogon japonicus, 1-3 parts cornus officinalis, and 1-3 parts cistanche deserticola. This traditional Chinese medicine composition has a unique and reasonable formulation, a simple preparation method, no toxic side effects, significant effects, low recurrence rate, and low adverse reactions.

Description

Technical Field

[0001] This invention relates to the field of traditional Chinese medicine technology, and in particular to a traditional Chinese medicine composition with weight loss effect and its application. Background Technology

[0002] Obesity is a metabolic disease caused by energy intake exceeding expenditure, with excess energy stored as fat, leading to increased fat cell size and excessive proliferation. With improved living standards and changing lifestyles, the incidence of obesity is on the rise. Its pathogenesis and treatment have become a hot topic in medical research. Studies show that genetic factors, environmental factors, lifestyle habits, and excessive dietary nutrition can all cause obesity. Obesity-related metabolic abnormalities, type 2 diabetes, cardiovascular diseases, and tumors impose a serious medical burden. Currently, weight-loss products used domestically and internationally are mainly Western medicines and dietary fiber products, including appetite suppressants, digestive blockers, hormones, and energy-boosting drugs, which have significant side effects. Traditional Chinese medicine (TCM) is characterized by its syndrome differentiation and treatment, and fewer side effects. Therefore, the research and development of safe and effective TCM for weight loss and lipid reduction has become an international research hotspot and has positive significance.

[0003] Existing technologies also disclose some traditional Chinese medicine compositions with weight-loss effects, such as the patent no. "CN202410778175.9" which discloses "A Traditional Chinese Medicine Composition with Weight-Loss Effect and Its Preparation Method and Application." This composition, by weight, consists of the following raw materials: 2-10 parts lotus leaf, 5-15 parts hawthorn, 5-10 parts Poria cocos, 5-15 parts roselle, 5-10 parts dried tangerine peel, 1-5 parts Gynostemma pentaphyllum, 1-5 parts pearl powder, and 2-10 parts tea leaves; the green tea is any one of Longjing, Biluochun, Xianhao, Maofeng, Cuiya, and Huangjinya. Although this patent discloses several components similar to those in the formula of this application, the preparation process of this patent application is complex, and the compatibility needs improvement. Summary of the Invention

[0004] In view of the shortcomings of the existing technology, the purpose of this invention is to develop a traditional Chinese medicine composition with weight loss effect and its application. The traditional Chinese medicine composition has a unique and reasonable formulation, no toxic side effects, obvious effect, low adverse reactions and low recurrence rate, and a simple and reasonable preparation method.

[0005] The technical solution of this invention is:

[0006] A traditional Chinese medicine composition with weight loss effect, the composition and dosage of the medicine are as follows: 5-10 parts roselle, 5-10 parts lotus leaf, 2-6 parts cassia seed, 2-6 parts radish seed, 2-6 parts coix seed, 2-6 parts poria cocos, 1-2 parts blood orange, 1-3 parts codonopsis pilosula, 1-2 parts astragalus membranaceus, 1-2 parts euryale ferox, 1-3 parts dendrobium officinale, 1-3 parts ophiopogon japonicus, 1-3 parts cornus officinalis, and 1-3 parts cistanche deserticola.

[0007] Alternatively, the drug formula and dosage by weight are as follows: 5-10 parts roselle, 5-10 parts lotus leaf, 2-6 parts cassia seed, 2-6 parts radish seed, 2-6 parts coix seed, 2-6 parts poria cocos, 1-2 parts blood orange, 1-3 parts codonopsis pilosula, 1-2 parts astragalus membranaceus, and 1-2 parts euryale ferox.

[0008] Preferably, the composition and weight parts of the traditional Chinese medicine composition are as follows: 7 parts roselle, 7 parts lotus leaf, 4 parts cassia seed, 4 parts radish seed, 4 parts coix seed, 4 parts poria cocos, 1 part blood orange, 2 parts codonopsis, 1 part astragalus, 1 part euryale seed, 2 parts dendrobium officinale, 2 parts ophiopogon japonicus, 2 parts cornus officinalis, and 2 parts cistanche deserticola.

[0009] Alternatively, the drug formula and weight parts are as follows: 7 parts roselle, 7 parts lotus leaf, 4 parts cassia seed, 4 parts radish seed, 4 parts coix seed, 4 parts poria cocos, 1 part blood orange, 2 parts codonopsis pilosula, 1 part astragalus membranaceus, and 1 part euryale ferox.

[0010] The preferred preparation method is as follows: The preparation method includes selecting roselle, lotus leaf, cassia seed, radish seed, coix seed, poria cocos, blood orange, codonopsis, astragalus, euryale seed, dendrobium officinale, ophiopogon japonicus, cornus officinalis and cistanche deserticola according to the above proportions, pulverizing them into fine powder, and passing them through a 60-80 mesh sieve to obtain the finished medicinal powder.

[0011] Furthermore, the finished pharmaceutical powder may be further formulated into one of tablets, granules, pills, capsules, and oral liquids using conventional techniques in the art.

[0012] The present invention also provides the application of the traditional Chinese medicine composition in the preparation of a medicament for treating obesity.

[0013] The prescription of this invention is explained as follows:

[0014] Principal drug

[0015] Roselle / Hibiscus has the effects of clearing heat and detoxifying, promoting blood circulation and removing blood stasis, and beautifying the skin. In this formula, it is the principal ingredient, mainly used for clearing heat and detoxifying, promoting blood circulation and removing blood stasis, improving blood circulation, promoting metabolism, and aiding in weight loss and beauty.

[0016] Lotus leaves clear heat and promote diuresis, while also clearing away turbidity. They can relieve summer heat, promote urination and reduce swelling, effectively alleviating symptoms caused by damp-heat and helping to eliminate excess water and fat from the body.

[0017] 2. Assistant Medicine:

[0018] Cassia seeds clear the liver and improve eyesight, and moisten the intestines to relieve constipation. Cassia seeds can clear liver fire and lower blood lipids, and have a good effect on red, swollen, and painful eyes caused by liver fire. At the same time, they help relieve constipation and reduce the accumulation of toxins in the body.

[0019] Semen Raphani promotes digestion and removes food retention, and descends qi to resolve phlegm. Semen Raphani can promote gastrointestinal peristalsis, aid digestion, reduce internal dampness and phlegm turbidity, and contribute to weight loss.

[0020] Coix Seed strengthens the spleen and promotes diuresis, clears heat and expels pus. Coix Seed can strengthen the spleen and promote diuresis, help remove internal dampness, and reduce fat accumulation.

[0021] Poria cocos promotes diuresis and percolates dampness, strengthens the spleen and soothes the mind. Poria cocos can promote diuresis and percolate dampness, help remove excess water in the body, strengthen the spleen and soothe the mind at the same time, and improve sleep quality.

[0022] 3. Assistant drugs

[0023] Blood orange is rich in vitamin C and antioxidants, which helps to enhance immunity, promote metabolism, and reduce fat accumulation.

[0024] Codonopsis pilosula replenishes middle qi and benefits qi, strengthens the spleen and nourishes the stomach. Codonopsis pilosula can enhance physical fitness, improve immunity, aid digestion and absorption at the same time, and reduce fatigue.

[0025] Astragalus membranaceus replenishes qi, strengthens the exterior, and promotes diuresis. Astragalus membranaceus can enhance the body's immunity, improve disease resistance, promote diuresis and reduce edema at the same time.

[0026] Gordon euryale seed strengthens the spleen and stops diarrhea, consolidates the kidney and astringes essence. Gordon euryale seed can strengthen the spleen and stop diarrhea, help improve digestive function, consolidate the kidney and astringe essence, and enhance physical fitness at the same time.

[0027] Dendrobium officinale nourishes yin and clears heat, promotes the production of body fluid and quenches thirst. Dendrobium officinale can nourish yin fluid, clear heat and detoxify. Ophiopogon japonicus nourishes yin and moistens the lungs, clears the heart and removes vexation. These two herbs are used as assistants to prevent the consumption of yin fluid caused by drugs such as clearing heat and detoxifying, promoting diuresis and relieving constipation.

[0028] Cornus officinalis tonifies the liver and kidney, astringes and arrests discharge. Cornus officinalis can tonify the liver and kidney, enhance physical fitness, and astringe and arrest discharge at the same time. Cistanche deserticola tonifies kidney yang, benefits essence and blood, moistens the intestine and promotes defecation, and helps to expel toxins from the body. These two herbs jointly restrict the drastic properties of the monarch drug and ministerial drug.

[0029] Compared with the prior art, the advantages of the present invention are:

[0030] 1. The pharmacodynamic research data of the present invention prove that the composition of the present invention can reduce the body weight of nutritional obesity rats to varying degrees and has a good improvement effect on abnormal lipid metabolism.

[0031] 2. The clinical use effect of the present invention proves that patients treated with the composition of the present invention can effectively reduce body weight, BMI, waist-hip ratio, triglyceride, and total cholesterol, and the results are close to those of the orlistat group. The effect is significant, the adverse reactions are small, the recurrence rate is low, the safety is high, and it is suitable for long-term use.

[0032] 4. The preparation method of the traditional Chinese medicine composition of the present invention is simple, and the effective rate of the clinical experiment is high.

[0033] 5. Compared with the comparative formulation, the drug synergistic effect between the drugs in the traditional Chinese medicine composition of the present invention is stronger and the therapeutic effect is better.

[0034] The detailed structure of the present invention will be further described below with reference to specific embodiments. Detailed Implementation

[0035] To make the objectives, technical solutions, and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below. Obviously, the described embodiments are some embodiments of the present invention, but not all embodiments.

[0036] The weight parts mentioned in the embodiments of the present invention refer to mass, and the units are generally g or kg. Example 1

[0037] A traditional Chinese medicine composition with weight loss effect, the drug composition and weight parts are as follows: 7 parts roselle, 7 parts lotus leaf, 4 parts cassia seed, 4 parts radish seed, 4 parts coix seed, 4 parts poria cocos, 1 part blood orange, 2 parts codonopsis, 1 part astragalus, 1 part euryale seed, 2 parts dendrobium officinale, 2 parts ophiopogon japonicus, 2 parts cornus officinalis, and 2 parts cistanche deserticola.

[0038] Preparation method: Grind the above fourteen herbs into fine powder, pass through a 60-80 mesh sieve to obtain the finished powder, and encapsulate it in a composite film of polyester / aluminum / polyethylene, etc., with each bag containing 2g. Comparative Example 1

[0039] A traditional Chinese medicine composition, the drug formula and weight parts are as follows: 7 parts roselle, 4 parts cassia seed, 4 parts radish seed, 1 part blood orange, 2 parts codonopsis, 1 part astragalus, and 1 part euryale seed.

[0040] The preparation method is the same as in Example 1: the above seven herbs are pulverized into fine powder, passed through a 60-80 mesh sieve to obtain the finished powder, and then packaged in a composite film of polyester / aluminum / polyethylene, etc., with each bag containing 2g. Example 2

[0041] A traditional Chinese medicine composition, the drug composition and weight parts are as follows: 7 parts roselle, 7 parts lotus leaf, 4 parts cassia seed, 4 parts radish seed, 4 parts coix seed, 4 parts poria cocos, 1 part blood orange, 2 parts codonopsis, 1 part astragalus, and 1 part euryale seed.

[0042] Preparation method: Grind the above ten herbs into fine powder, pass through a 60-80 mesh sieve to obtain the finished powder, and wrap it with a composite film of polyester / aluminum / polyethylene, etc., with each bag containing 2g.

[0043] Example 3: Animal pharmacodynamic experimental data

[0044] Experiment 1: Effects of the traditional Chinese medicine composition of Example 1 and the comparative traditional Chinese medicine composition on an obese rat model

[0045] 1. Experimental objective:

[0046] This experiment investigated the therapeutic effect of the composition of Example 1 on nutritionally obese rats by replicating an obese rat model, providing a pharmacological basis for the clinical application of the composition of Example 1.

[0047] 2. Test materials:

[0048] Test substance (test sample): The composition of Example 1 (Guyitang (Hunan) Health Technology Co., Ltd.), the composition of Comparative Example 1 (Guyitang (Hunan) Health Technology Co., Ltd.), the composition of Example 2 (Guyitang (Hunan) Health Technology Co., Ltd.), the intended route of clinical use: oral administration, 2g once, 3 times a day, the intended course of clinical treatment: 3 months, positive control group, name: sibutramine hydrochloride capsules, manufacturer: Hainan General Sanyo Pharmaceutical Co., Ltd.; experimental animals: SPF grade, 75 male SD rats, weight range: 180-220g.

[0049] 3. Methods

[0050] 3.1 Establishment of a Nutritional Obesity Model in Rats and Animal Treatment: Seventy-five male SPF SD rats were randomly divided into a normal control group (n=10) and other groups (n=65). The normal control group was fed a standard diet, while the other groups were fed a nutritional diet. The nutritional diet formula was as follows: per 100g of standard diet, 10g of milk powder, 10g of lard, 1 egg, 10 drops of concentrated cod liver oil (17000U of vitamin A and 1700U of vitamin D), and 250g of fresh soybean sprouts were added, increasing by 2g weekly until the 6th week. The diet was given twice daily, with no further feed added after the initial feeding. Obesity was defined as rats on the nutritional diet exceeding the weight of rats on the standard diet by 20%. Fifty obese rats were selected and randomly divided into a model control group, a sibutramine group (positive control), a ratio 1, Example 2, and Example 1, with 10 rats in each group. Sibutramine group (positive control), ratio 1, Example 2, and Example 1 were administered once daily by gavage at a volume of 10 mL / kg. The model control group was administered the same volume of 0.5% sodium carboxymethyl cellulose by gavage for 4 consecutive weeks. Body weight was measured weekly. After the last administration and a 24-hour fast, blood was collected from the abdominal aorta under chloral hydrate anesthesia, centrifuged at 3000 r / min for 10 min, and serum was separated and stored at -70℃ for later use. Perirenal and peritesticular fat were collected and weighed wet. A small piece of adipose tissue from the same area around the genitals was also collected, fixed with 2.5% formaldehyde ethanol solution, and the number and diameter of adipocytes were counted under a 400x microscope. 2.2 Serum triglyceride (TG) and total cholesterol (TC) levels were measured using an automated biochemical analyzer.

[0051] 3.2 Dosage setting

[0052] The clinically intended dose of the compositions in Example 1, Comparative Example 1, and Example 2 was 6 g / day. The equivalent clinical dose for rats, calculated based on body surface area, was: adult dose × 0.018 × 5 = 0.54 g / kg. The dose for the sibutramine hydrochloride (positive control group) group was set at 0.008 g / kg.

[0053] 3.3 Calculation and Statistics of Results

[0054] SPSS 21.0 software was used for statistical analysis. Experimental data are expressed as mean ± standard deviation (x±S). For comparisons among multiple groups, normality and homogeneity of variance were first compared. If the variances were homogeneous and normality was observed, one-way ANOVA was used. If normality was not observed, the nonparametric t-test was used. If normality was observed but variances were unequal, Tamhane's t² test was used. If normality was not observed, the Kruskal-Wallis test was used. Pairwise comparisons were performed using the Mann-Whitney test. P < 0.05 was considered statistically significant, and P < 0.01 was considered highly significant.

[0055] 4. Experimental Results

[0056] 4.1 Effects on body weight and fat in a nutritionally obese rat model

[0057] As shown in Table 1, compared with the blank control group, the body weight, perirenal fat wet weight, and peritesticular fat wet weight of rats in the model control group were significantly increased (P<0.01); compared with the model control group, the body weight, perirenal fat wet weight, and peritesticular fat wet weight of rats in Comparative Example 1, Example 2, Example 1, and the positive control group were significantly decreased (P<0.05 or P<0.01); compared with Comparative Example 1 and Example 2, the body weight, perirenal fat wet weight, and peritesticular fat wet weight of rats in Example 1 were significantly decreased (P<0.05 or P<0.01); there was no statistically significant difference between Example 1 and the positive control group (P>0.05); compared with Comparative Example 1, the body weight, perirenal fat wet weight, and peritesticular fat wet weight of rats in Example 2 were significantly decreased (P<0.05). The results are shown in Table 1.

[0058]

[0059] As shown in Table 2, compared with the blank control group, the levels of TG and TC in the rats of the model control group were significantly increased (P<0.01); compared with the model control group, the levels of TG and TC in rats of Comparative Example 1, Example 2, Example 1, and the positive control group were significantly decreased (P<0.05 or P<0.01); the levels of TG and TC in Example 1 were significantly decreased compared with Comparative Example 1 and Example 2 (P<0.05 or P<0.01); there was no statistically significant difference in TG and TC between Example 1 and the positive control group (P>0.05); and the levels of TC in Example 2 were significantly decreased compared with Comparative Example 1 (P<0.05). The results are shown in Table 2.

[0060]

[0061] As shown in Table 3, compared with the blank control group, the number of rat cells in the model control group was significantly decreased (P<0.01) and the cell diameter was significantly increased (P<0.01). Compared with the model control group, the number of rat cells in Comparative Example 1, Example 2, Example 1, and the positive control group was significantly increased (P<0.05 or P<0.01), and the cell diameter was significantly decreased (P<0.05 or P<0.01). Compared with Comparative Example 1 and Example 2, Example 1 showed a significantly increased number of rat cells (P<0.05 or P<0.01) and a significantly decreased cell diameter (P<0.05 or P<0.01). There was no statistically significant difference between Example 1 and the positive control group (P>0.05). Compared with Comparative Example 1, Example 2 showed a significantly increased number of rat cells (P<0.05) and a significantly decreased cell diameter (P<0.05). The results are shown in Table 3.

[0062]

[0063] 5. Conclusion: Under the conditions of this experiment, the compositions of Comparative Example 1, Example 2, and Example 1 could increase the number of cells in nutritionally obese rats to varying degrees, significantly reduce the cell diameter in highly nutritious obese rats, reduce TG and TC levels, and reduce body weight, perirenal fat wet weight, and peritesticular fat wet weight. Example 1 showed better efficacy than Comparative Example 1 and Example 2. The synergistic effect of the drugs in Example 1 was significantly greater than that in Comparative Example 1 and Example 2.

[0064] Example 4: Clinical analysis data of the traditional Chinese medicine composition from Example 1

[0065] General Information: 122 patients meeting the diagnostic criteria for pure obesity were selected for observation and randomly divided into Example 1 and a control group. Example 1 group consisted of 35 males and 26 females, aged 20–60 years, with a mean age of (43.27±6.14) years and a disease duration of 8 months to 6 years. The control group consisted of 33 males and 28 females, aged 20–60 years, with a mean age of (42.85±6.63) years and a disease duration of 8 months to 7 years. There were no statistically significant differences in general characteristics between the two groups (P>0.05), indicating comparability.

[0066] Inclusion criteria: Obese patients who meet the Western medicine diagnostic criteria for simple obesity; obese patients who meet the TCM constitution criteria for phlegm-dampness; patients aged between 18 and 65 years; all patients meet the diagnostic criteria for obesity, with a weight exceeding the standard weight by 20% or a BMI exceeding 24.

[0067] Exclusion criteria: pregnant or lactating women; those allergic to Chinese medicine ingredients; those with severe complications of the heart, liver, kidneys, or brain, or those with other serious primary diseases; and those with mental illness.

[0068] Treatment methods: The control group received orlistat (produced by Chongqing Huasen Pharmaceutical Co., Ltd., National Drug Approval Number H20103180) taken with or within one hour after meals, 1 tablet / time, 3 times / day; the Example 1 group received the product of Example 1 of this invention orally (provided by Guyitang (Hunan) Health Technology Co., Ltd., 2g / bag), 1 bag each time, 3 times a day. Both groups of patients were treated continuously for 3 months. During the medication period, patients were prohibited from consuming rich, greasy, sticky, heavy, and difficult-to-digest foods, reduced the amount of staple food, increased the amount of vegetables and fruits, and appropriately increased the amount of exercise.

[0069] Criteria for evaluating therapeutic efficacy:

[0070] Cure: Clinical symptoms completely disappear and weight returns to normal; Significant effect: Most clinical symptoms disappear and weight decreases by more than 5 kg; Effective: Clinical symptoms are somewhat relieved and weight decreases by more than 3 kg; Ineffective: Clinical symptoms show no significant improvement and weight decreases by less than 3 kg.

[0071] Observation indicators:

[0072] Observe changes in weight, BMI, waist circumference, waist-to-hip ratio, and blood lipids (triglycerides and total cholesterol) before and after treatment. Observe whether there are any adverse reactions such as gastrointestinal reactions, fatty stools, abdominal pain, discomfort, or allergies during treatment. Follow up for 1 year and record the recurrence of obesity.

[0073] Statistical methods: SPSS 16.0 statistical software was used for data processing and analysis in this study. The t-test was used to compare continuous data, and the chi-square test was used to compare categorical data. P < 0.05 was considered statistically significant.

[0074]

[0075]

[0076]

[0077]

[0078] As shown in Tables 4-7, the following comparisons were made between the two groups of patients before and after treatment: Before treatment, there were no statistically significant differences in weight, BMI, waist-to-hip ratio, triglycerides, and total cholesterol between the two groups (P > 0.05); After treatment, the weight, BMI, waist-to-hip ratio, triglycerides, and total cholesterol in both groups were lower than before treatment (P < 0.05 or P < 0.01). After treatment, the weight, BMI, waist-to-hip ratio, triglycerides, and total cholesterol in the control group were similar to those in the Example 1 group, with no statistically significant differences (P > 0.05). Adverse reaction observation and comparison: The incidence of adverse reactions in the Example 1 group after treatment was lower than that in the control group, with a statistically significant difference (P < 0.05). Recurrence rate observation and comparison: The incidence of adverse reactions in the Example 1 group after treatment was lower than that in the control group, with a statistically significant difference (P < 0.05).

[0079] The above description is a specific embodiment of the present invention, but the scope of protection of the present invention is not limited thereto. Any equivalent substitutions or modifications made by those skilled in the art within the scope of the technology disclosed in the present invention, based on the technical solution and concept of the present invention, should be covered within the scope of protection of the claims of the present invention.

Claims

1. A traditional Chinese medicine composition with weight-loss effect, characterized in that, The drug composition and dosage by weight are as follows: 5-10 parts roselle, 5-10 parts lotus leaf, 2-6 parts cassia seed, 2-6 parts radish seed, 2-6 parts coix seed, 2-6 parts poria cocos, 1-2 parts blood orange, 1-3 parts codonopsis pilosula, 1-2 parts astragalus membranaceus, 1-2 parts euryale ferox, 1-3 parts dendrobium officinale, 1-3 parts ophiopogon japonicus, 1-3 parts cornus officinalis, and 1-3 parts cistanche deserticola. Alternatively, the drug formula and dosage by weight are as follows: 5-10 parts roselle, 5-10 parts lotus leaf, 2-6 parts cassia seed, 2-6 parts radish seed, 2-6 parts coix seed, 2-6 parts poria cocos, 1-2 parts blood orange, 1-3 parts codonopsis pilosula, 1-2 parts astragalus membranaceus, and 1-2 parts euryale ferox.

2. The traditional Chinese medicine composition with weight-loss effect according to claim 1, characterized in that, The drug formula and weight parts are as follows: 7 parts roselle, 7 parts lotus leaf, 4 parts cassia seed, 4 parts radish seed, 4 parts coix seed, 4 parts poria cocos, 1 part blood orange, 2 parts codonopsis, 1 part astragalus, 1 part euryale seed, 2 parts dendrobium officinale, 2 parts ophiopogon japonicus, 2 parts cornus officinalis, and 2 parts cistanche deserticola. Alternatively, the drug formula and weight parts are as follows: 7 parts roselle, 7 parts lotus leaf, 4 parts cassia seed, 4 parts radish seed, 4 parts coix seed, 4 parts poria cocos, 1 part blood orange, 2 parts codonopsis pilosula, 1 part astragalus membranaceus, and 1 part euryale ferox.

3. A method for preparing a traditional Chinese medicine composition with weight-loss effect according to any one of claims 1-2, characterized in that: The preparation method includes selecting roselle, lotus leaf, cassia seed, radish seed, coix seed, poria cocos, blood orange, codonopsis, astragalus, euryale seed, dendrobium officinale, ophiopogon japonicus, cornus officinalis and cistanche deserticola according to the above proportions, pulverizing them into fine powder, and passing them through a 60-80 mesh sieve to obtain the finished medicinal powder.

4. The method for preparing a traditional Chinese medicine composition with weight-loss effect according to claim 3, characterized in that: The finished pharmaceutical powder may be further formulated into one of the following formulations: tablets, granules, pills, capsules, and oral liquids, using conventional techniques in the field.

5. The use of the traditional Chinese medicine composition according to any one of claims 1-2 in the preparation of a medicament for treating obesity.

Images